Opinion|Videos|April 14, 2026
Exploring ADCs in HR+ Breast Cancer Care
Author(s)Neil Iyengar, MD, Kelsey Natsuhara, MD
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss the role of antibody-drug conjugates in the management of hormone receptor–positive breast cancer.
Advertisement
Episodes in this series
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, evaluate the role of antibody-drug conjugates (ADCs) in hormone receptor–positive breast cancer management. Iyengar reviews how agents such as fam-trastuzumab deruxtecan-nxki (Enhertu) and TROP2-directed ADCs are being incorporated into treatment paradigms, particularly for HER2-low disease. Natsuhara discusses sequencing considerations and how clinicians balance ADC use with endocrine-based and targeted therapies.
Advertisement
Related to this article
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
A study found that the vast majority of veterans with early prostate cancer pursued surveillance instead of treatment.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
3
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
4
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
5